Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Be the first to review this product

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Summary

Immunology is a large therapy area characterized by disorders...
You can choose to pay by purchase order during checkout

Availability: In stock

$6,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GBI Research.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

Frontier Pharma: Versatile Innovation in Immunology - Large Therapy Area Pipeline with a High Degree of Repositioning Potential

Summary

Immunology is a large therapy area characterized by disorders of the immune system _ specifically an aberrant immune response against healthy tissues present in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and loss of mobility, and have a negative impact on quality of life.

This disease area has a total of 2,145 products in active development, trailing only oncology, infectious diseases and central nervous system disorders in terms of pipeline size. There are a total of 529 immunology pipeline products that act on first-in-class molecular targets, representing approximately 40% of the total immunology pipeline for which the molecular target was disclosed.

Due to a degree of crossover between immunology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications.

Approximately one-fifth of first-in-class pipeline products are in development for two or more indications within the therapy area. This presents an opportunity for companies to develop innovative products across multiple immune disorders, and therefore reach a larger pool of patients than products developed for single indications.

Scope

- What are the key points of overlap in the pathophysiology of immune disorders?
- What is the current standard of treatment across these markets, and what lessons can be learned by companies seeking to innovate and build on these products?
- Which molecule types and molecular targets are most prominent within the pipeline?
- Which first-in-class targets are most promising?
- Do immunology products attract high deal values, and which specific product types are able to attract the highest values?
- Which molecule types and molecular targets dominate the deals landscape?

Reasons to buy

- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options.
- Identify leading products and companies within the market, as well as key unmet needs, in order to gain a competitive understanding of gaps in the market.
Review key pipeline trends by analyzing therapies by stage of development, molecule type and molecular target, and identify key trends regarding innovation within each segment.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the immunology pipeline have been assessed and ranked according to clinical potential, and the most promising early-stage targets have been further reviewed in greater detail.
- Identify promising first-in-class pipeline assets that have had no prior involvement in licensing or co-development deals, and are therefore potentially suitable for in-licensing.

Additional Information

Additional Information

Publisher name GBI Research.
Format PDF
Page count 80
Publication date 5 Jan 2017
Table of contents 1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Executive Summary 5
2.1 Large Therapy Area Characterized by a High Degree of Pathophysiological Crossover 5
2.2 Strong Pipeline Shows High Level of Versatile Innovation 5
2.3 Substantial Deal Making Activity Observed over the Past Decade 5
3 The Case for Innovation in the Immunology Market 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
4 Introduction 9
4.1 Therapy Area Introduction 9
4.2 Symptoms 9
4.3 Etiology and Pathophysiology 9
4.3.1 Innate Immunity 9
4.3.2 Adaptive Immunity 10
4.3.3 The Role of Cytokines 11
4.3.4 Autoimmunity 11
4.3.5 Etiologic Factors for Autoimmunity and Allergies 12
4.3.6 Conclusion 12
4.4 Co-morbidities and Complications 13
4.5 Epidemiology 13
4.6 Treatment 14
4.6.1 Non-Biologic Disease-Modifying Anti-Rheumatic Drugs 15
4.6.2 Glucocorticoids 15
4.6.3 Biologics and Targeted Therapies 15
5 Pipeline Landscape Assessment 17
5.1 Overview 17
5.2 Pipeline Development Landscape 18
5.3 Molecular Targets in the Pipeline 19
5.4 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family 20
5.5 First-in-Class and Versatile Pipeline Programs 21
5.6 First-in-Class Immunology Products by Phase, Molecule Type and Molecular Target 23
5.7 Versatility of First-in-Class Pipeline Products 26
6 Immunology Signaling Network, Disease Causation and Innovation Alignment 35
6.1 Complexity of Signaling Networks 35
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 35
6.3 First-in-Class Matrix Assessment 35
7 First-in-Class Target and Pipeline Program Evaluation 40
7.1 Pipeline Programs Targeting Toll-Like Receptors 3, 6 and 8 40
7.2 Pipeline Programs Targeting Spleen Tyrosine Kinase 44
7.3 Pipeline Programs Targeting IL-7R 46
7.4 Pipeline Programs Targeting C-C Chemokine Receptor Type 6 47
7.5 Pipeline Programs Targeting P2RX7 48
7.6 Pipeline Programs Targeting ITK 50
7.7 Pipeline Programs Targeting IRAK4 51
7.8 Pipeline Programs Targeting Orai1 52
7.9 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 54
7.10 Conclusion 55
8 Strategic Consolidations 56
8.1 Industry-Wide First-in-Class Deals 56
8.2 Licensing Deals 57
8.2.1 Deals by Region, Year and Value 58
8.2.2 Deals by Stage of Development and Value 59
8.2.3 Deals by Molecule Type and Value 60
8.2.4 Deals by Molecular Target and Value 61
8.3 Co-development Deals 62
8.3.1 Deals by Region, Year and Value 62
8.3.2 Deals by Stage of Development and Value 64
8.3.3 Deals by Molecule Type and Value 65
8.3.4 Deals by Molecular Target and Value 66
8.4 List of First-in-Class Pipeline Products with and Without Prior Deal Involvement 67
9 Appendix 72
9.1 Abbreviations 72
9.2 References 72
9.3 Research Methodology 78
9.3.1 Data integrity 78
9.3.2 Innovative and meaningful analytical techniques and frameworks 78
9.3.3 Evidence based analysis and insight 78
9.4 Secondary Research 79
9.4.1 Market Analysis 79
9.4.2 Pipeline Analysis 79
9.4.3 Licensing and Co-development Deals 80
9.5 Contact Us 80
9.6 Disclaimer 80

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.